Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Riordan (Gilead Sciences) Schmergel (Genetics Institute) Vincent (Biogen) Biotech Roundtable 1991 by G Steven Burrill


Published on

Michael L Riordan, the founder & CEO of Gilead, Gabriel Schmergel, the CEO of Genetics Institute, and James L Vincent, the CEO of Biogen, are interviewed by G Steven Burrill regarding the state of the Biotech industry. 1991.

Published in: Business
  • Be the first to comment

Riordan (Gilead Sciences) Schmergel (Genetics Institute) Vincent (Biogen) Biotech Roundtable 1991 by G Steven Burrill

  1. 1. James L. Vincent Chairman and Chief Executive Officer Biogen, Inc. James L. Vincent, earlier President of Allied Health and Scientific Products and COO of Abbott Laboratories, joined Biogen as Chairman and CEO in 1985. At the time, the Cambridge company, foun­ ded in 1978, was floundering. Mr. Vincent engi­ neered a remarkable turnaround, and in 1989 Ied the company to its first year of profitability. Biogen's products-and-relationships portfolio include hepa­ titis B antigens (Abbott Laboratories, Ortho Diag­ nostic Systems), hepatitis B vaccine (Merck), alpha interferon (Schering-Plough), gamma interferon (Rentschler, Shionogi). Products in research or development include CD4 for AIDS therapy (with funding from New York Life Insurance Company); thrombin inhibitors and a platelet receptor antago­ nist for the treatment of cardiovascular disease; and vascular cell-adhesion molecule inhibitors as treat­ mentfor inflammation and autoimmune diseases. liif!iiiiif:ii@ijj• Michael Riordan, M.D. President and Chief Executive Officer Gilead Sciences, Inc. Michael Riordan brought a broad background to the creation of Gilead Sciences. He holds an M.D. degree from Johns Hopkins, a Harvard M.B.A., a B.S. in chemical engineering, and a B.A. in biol­ ogy. He founded the Foster City, CA, company in 1987, while working as a venture capitalist at Menlo Ventures. Earlier, he was an international lending officer at the Industrial Bank of Japan in Tokyo, a consultant with McKinsey & Co. and Arthur D. Little, and a Luce Fellow in East Asia. Gilead Sciences is developing a new class of phar­ maceuticals which employ antisense technology and other methods to inhibit disease processes at the DNA and RNA level. Its primary disease tar­ gets are severe viral infections and oncogene­ derived cancers for which no adequate therapies exist. The company's investors include Menlo Ven­ tures; J. H. Whitney & Co.; Venrock Associates; Merrill, Pickard, Anderson & Eyre; Concord Partners; William Blair Venture Partners; John Hancock Venture Capital; the Vista Group; and Abingworth Management Limited. Two months after this roundtable, Gilead signed $20 million strategic alliance with Glaxo. 95